Vor Biopharma Inc
$ 16.59
10.82%
17 Apr - close price
- Market Cap 810,380,000 USD
- Current Price $ 16.59
- High / Low $ 16.86 / 15.00
- Stock P/E N/A
- Book Value -8.10
- EPS -70.50
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.70 %
- ROE -1.25 %
- 52 Week High 65.80
- 52 Week Low 2.62
About
Vor Biopharma, Inc., an early stage cell therapy company, develops hematopoietic stem cell (eHSC) therapies designed for cancer patients. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$37.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-31 | 2025-12-31 | 2025-11-13 | 2025-08-12 | 2025-05-07 | 2025-03-18 | 2024-11-05 | 2024-08-08 | 2024-05-09 | 2024-03-20 | 2023-11-07 | 2023-08-10 |
| Reported EPS | 44.4951 | 307.53 | -121.6 | -251.24 | -0.26 | -0.44 | -0.4 | -0.41 | -0.45 | -0.39 | -0.49 | -0.45 |
| Estimated EPS | None | -1.191 | -0.1 | -0.2243 | -0.208 | -0.3067 | -0.4 | -0.42 | -0.38 | -0.5 | -0.47 | -0.43 |
| Surprise | 0 | 308.721 | -121.5 | -251.0157 | -0.052 | -0.1333 | 0 | 0.01 | -0.07 | 0.11 | -0.02 | -0.02 |
| Surprise Percentage | None% | 25921.1587% | -121500% | -111910.7% | -25% | -43.4627% | 0% | 2.381% | -18.4211% | 22% | -4.2553% | -4.6512% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.75 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VOR
2026-04-20 17:09:32
Vor Biopharma (NASDAQ: VOR) saw its stock price drop by 4.4% on Monday, trading as low as $15.49 and closing at $15.8650, with significantly reduced trading volume. This decline occurred despite analysts maintaining a "Moderate Buy" consensus and an average price target of $50.56 for the company. Notably, there was significant insider selling, including Ra Capital divesting 589,257 shares for approximately $9.8 million on April 6th, leading to corporate insiders owning only 0.45% of the company's stock.
2026-04-16 11:39:48
H.C. Wainwright lowered its price target for Vor Biopharma (NASDAQ:VOR) to $31 from $32, while maintaining a Buy rating. The company has shifted focus from oncology to autoimmune therapies with telitacicept, currently in two global Phase 3 trials for generalized myasthenia gravis and Sjogren’s disease. Despite burning cash, Vor Biopharma holds more cash than debt and is considered undervalued by InvestingPro analysis.
2026-04-16 00:09:57
Ra Capital Management, L.P. sold 530,610 shares of Vor Biopharma (NASDAQ:VOR) on April 13th for over $8.5 million, reducing its stake by 13.48%. This sale is part of a series of transactions in early April, totaling approximately 2.21 million shares sold for about $36.6 million. Vor Biopharma currently trades near $15.60, with significant institutional ownership and a consensus analyst "Moderate Buy" rating.
2026-04-15 22:09:33
Ra Capital Management, L.P., a director at Vor Biopharma (NASDAQ:VOR), sold 153,735 shares of the company's stock on April 14th at an average price of $15.97, totaling approximately $2.46 million. This sale is part of several disposals made by the firm in April, amounting to about $28.1 million and reducing their stake by 4.51% to 3,251,263 shares. Despite the insider selling, analysts maintain a "Moderate Buy" consensus rating for Vor Biopharma with an average price target of $50.56.
2026-04-15 21:09:57
RA Capital Management and affiliated funds have reported a 19.9% beneficial ownership in Vor Biopharma (VOR) common stock, totaling 12,739,024 shares as of March 30, 2026. This stake includes common shares, common stock warrants, and pre-funded warrants, although "Beneficial Ownership Blockers" limit the exercise of some warrants. The filing also disclosed recent open market sales by RA Capital's fund, totaling over 738,000 shares between April 13-15, 2026, at weighted average prices ranging from $15.97 to $16.15.
2026-04-15 21:09:57
Entities associated with RA Capital, including RA Capital Healthcare Fund, L.P., sold a total of 737,989 shares of Vor Biopharma (VOR) common stock in open-market transactions over three days (April 13-15, 2026) at weighted average prices around $16 per share. Following these sales, RA Capital-related entities still hold 3,197,619 shares of Vor Biopharma common stock, maintaining a significant position. The filing clarifies that RA Capital Management and its principals disclaim beneficial ownership beyond their pecuniary interest, indicating these were fund-level portfolio adjustments.
